Accueil
Explorer
nav.journalClub
Tendances
Plus
synapse
⌘+K
Langue
Français
Français
March 3, 2026
Trial in Progress: QUINTESSENTIAL—a Phase 2 study of Arlocabtagene Autoleucel (arlo-cel) in Patients with relapsed/refractory Multiple Myeloma (RRMM)
CF
Ciara L Freeman
NJ
Nisha Joseph
Emory University
SL
Sarah M Larson
See all
Key Points
Arlocabtagene autoleucel demonstrates potential effectiveness in treating relapsed/refractory multiple myeloma.
Key evidence includes significant responses observed with arlocabtagene in early trials, showing promise for this patient population.
Phase 2 study design focuses on the safety and efficacy of arlocabtagene autoleucel in patients with RRMM.
Potential for advancing treatment options in multiple myeloma, indicating a need for further investigations.
Mark Helpful
Like
Save
Bookmark
Relay
Share
Mark Helpful
Like
Save
Bookmark
Relay
Share
Cite This Study
Copy
Freeman et al. (Sun,) studied this question.
synapsesocial.com/papers/69a760a7c6e9836116a2d9de
https://doi.org/https://doi.org/10.1016/j.jtct.2025.12.282
Trial in Progress: QUINTESSENTIAL—a Phase 2 study of Arlocabtagene Autoleucel (arlo-cel) in Patients with relapsed/refractory Multiple Myeloma (RRMM) | Synapse